Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000-15: an analysis of pharmaceutical sales data

被引:303
作者
Klein, Eili Y. [1 ,2 ,3 ]
Milkowska-Shibata, Maja [1 ]
Tseng, Katie K. [1 ]
Sharland, Mike [4 ]
Gandra, Sumanth [5 ]
Pulcini, Celine [6 ,7 ]
Laxminarayan, Ramanan [1 ,8 ,9 ]
机构
[1] Ctr Dis Dynam Econ & Policy, Washington, DC 20005 USA
[2] Johns Hopkins Sch Med, Dept Emergency Med, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[4] St Georges Univ London, Paediat Infect Dis Res Grp, Inst Infect & Immun, London, England
[5] Washington Univ, Sch Med, Dept Internal Med, Div Infect Dis, St Louis, MO 63110 USA
[6] Univ Lorraine, APEMAC, Nancy, France
[7] Univ Lorraine, Dept Infect Dis, Nancy, France
[8] Princeton Univ, Princeton Environm Inst, Princeton, NJ 08544 USA
[9] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
关键词
EUROPE;
D O I
10.1016/S1473-3099(20)30332-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background The WHO Access, Watch, and Reserve (AWaRe) antibiotic classification framework aims to balance appropriate access to antibiotics and stewardship. We aimed to identify how patterns of antibiotic consumption in each of the AWaRe categories changed across countries over 15 years. Methods Antibiotic consumption was classified into Access, Watch, and Reserve categories for 76 countries between 2000, and 2015, using quarterly national sample survey data obtained from IQVIA. We measured the proportion of antibiotic use in each category, and calculated the ratio of Access antibiotics to Watch antibiotics (access-to-watch index), for each country. Findings Between 2000, and 2015, global per-capita consumption of Watch antibiotics increased by 90.9% (from 3.3 to 6.3 defined daily doses per 1000 inhabitants per day [DIDs]) compared with an increase of 26.2% (from 8.4 to 10.6 DIDs) in Access antibiotics. The increase in Watch antibiotic consumption was greater in lowincome and middle-income countries (LMICs; 165.0%; from 2.0 to 5.3 DIDs) than in high-income countries (HICs; 27.9%; from 6.1 to 7.8 DIDs). The access-to-watch index decreased by 38.5% over the study period globally (from 2.6 to 1.6); 46.7% decrease in LMICs (from 3.0 to 1.6) and 16.7% decrease in HICs (from 1.8 to 1.5), and 37 (90%) of 41 LMICs had a decrease in their relative access-to-watch consumption. The proportion of countries in which Access antibiotics represented at least 60% of their total antibiotic consumption (the WHO national-level target) decreased from 50 (76%) of 66 countries in 2000, to 42 (55%) of 76 countries in 2015. Interpretation Rapid increases in Watch antibiotic consumption, particularly in LMICs, reflect challenges in antibiotic stewardship. Without policy changes, the WHO national-level target of at least 60% of total antibiotic consumption being in the Access category by 2023, will be difficult to achieve. The AWaRe framework is an important measure of the effort to combat antimicrobial resistance and to ensure equal access to effective antibiotics between countries. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码:107 / 115
页数:9
相关论文
共 30 条
[1]   The inappropriate use of antibiotics in hospitalized dengue virus-infected children with presumed concurrent bacterial infection in teaching and private hospitals in Bandung, Indonesia [J].
Adrizain, Riyadi ;
Setiabudi, Djatnika ;
Chairulfatah, Alex .
PLOS NEGLECTED TROPICAL DISEASES, 2019, 13 (06)
[2]   The threat of antimicrobial resistance in developing countries: causes and control strategies [J].
Ayukekbong, James A. ;
Ntemgwa, Michel ;
Atabe, Andrew N. .
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2017, 6
[3]   Measuring trends of outpatient antibiotic use in Europe: jointly modelling longitudinal data in defined daily doses and packages [J].
Bruyndonckx, Robin ;
Hens, Niel ;
Aerts, Marc ;
Goossens, Herman ;
Molenberghs, Geert ;
Coenen, Samuel .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (07) :1981-1986
[4]   Targets for the reduction of antibiotic use in humans in the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) partner countries [J].
D'Atri, Fabio ;
Arthur, Jacqueline ;
Blix, Hege Salvesen ;
Hicks, Lauri A. ;
Plachouras, Diamantis ;
Monnet, Dominique L. ;
Strauss, Reinhild ;
Ingenbleek, Anne ;
Christova, Iva ;
Tambic Andrasevic, Arjana ;
Zemlickova, Helena ;
Moloney, Christina ;
Martin, Pille ;
Jalava, Jari ;
Cavalie, Philippe ;
Eckmanns, Tim ;
Kontopidou, Flora ;
Matuz, Maria ;
Gudnason, Thorolfur ;
Burns, Karen ;
Iannazzo, Stefania ;
Nikiforova, Raina ;
Valinteliene, Rolanda ;
Guerin, Valerie ;
Borg, Michael A. ;
de Greeff, Sabine ;
Steinbakk, Martin ;
Olczak-Pienkowska, Anna ;
Serban, Roxana ;
Schreterova, Eva ;
Cizman, Milan ;
Lopez Navas, Antonio ;
Stahlgren, Gunilla Skoog ;
Johnson, Alan ;
Reilly, Jacqui .
EUROSURVEILLANCE, 2019, 24 (28) :2-12
[5]   Health financing policies - Providers' opinions and prescribing behavior in rural China [J].
Dong, HJ ;
Bogg, L ;
Rehnberg, C ;
Diwan, CV .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1999, 15 (04) :686-698
[6]   Understanding Antibiotic Use in Minya District, Egypt: Physician and Pharmacist Prescribing and the Factors Influencing Their Practices [J].
Dooling, Kathleen L. ;
Kandeel, Amr ;
Hicks, Lauri A. ;
El-Shoubary, Waleed ;
Fawzi, Khaled ;
Kandeel, Yasser ;
Etman, Ahmad ;
Lohiniva, Anna Leena ;
Talaat, Maha .
ANTIBIOTICS-BASEL, 2014, 3 (02) :233-243
[7]  
Frost Isabel, 2019, Access barriers to antibiotics
[8]   Opportunities and barriers to implementing antibiotic stewardship in low and middle-income countries: Lessons from a mixed-methods study in a tertiary care hospital in Ethiopia [J].
Gebretekle, Gebremedhin Beedemariam ;
Mariam, Damen Haile ;
Abebe, Workeabeba ;
Amogne, Wondwossen ;
Tenna, Admasu ;
Fenta, Teferi Gedif ;
Libman, Michael ;
Yansouni, Cedric P. ;
Semret, Makeda .
PLOS ONE, 2018, 13 (12)
[9]   Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries [J].
Goossens, Herman ;
Ferech, Matus ;
Coenen, Samuel ;
Stephens, Peter .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (08) :1091-1095
[10]  
*HLTH ACT INT, 2011, MED PRIC AV AFF PRIC